Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis
In this real-world cohort, enfortumab vedotin-pembrolizumab combination demonstrated meaningful clinical activity and manageable toxicity in both first-line and subsequent-line settings, consistent with results from the EV-302 trial.
Authors
- Nikita Tripathi (ORCID: https://orcid.org/0000-0003-3499-3613)
- Jacob J. Orme (ORCID: https://orcid.org/0000-0002-0319-0239)
- Ruqin Chen
- Daniel S. Childs (ORCID: https://orcid.org/0000-0001-7643-2836)
- Prateek Jain
- J. K. Oberoi
- Irbaz Bin Riaz (ORCID: https://orcid.org/0000-0003-4249-0311)
- Muhammad Abdullah Humayun
- Yousef Zakharia (ORCID: https://orcid.org/0000-0001-9480-2626)
- Adam M. Kase (ORCID: https://orcid.org/0000-0002-1862-8467)
- Syed Arsalan Ahmed Naqvi (ORCID: https://orcid.org/0000-0002-3131-2088)
- Parminder Singh (ORCID: https://orcid.org/0000-0002-2851-6805)
Institutions
- Sinai Hospital (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.clgc.2025.102453
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02